Pharmaceutical
In what looks to be the largest follow-on stock offering in biopharma history, US oncology company Revolution Medicines priced 10.56 million shares to raise $1.5 billion and $500 million in convertible senior notes due 2033. 16 April 2026
Biotechnology
USA-based Galera Therapeutics and Obsidian Therapeutics, a privately-held clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocyte (TIL) cell therapies, announced that they have entered into a definitive merger agreement to combine in an all-stock transaction. 15 April 2026
Biotechnology
Texan pre-clinical stage biotech CrossBridge Bio, a developer of dual-payload antibody-drug conjugates (ADCs), has announced a definitive agreement to be acquired by US pharma major Eli Lilly. 14 April 2026
Biotechnology
US biotech major Regeneron Pharmaceuticals and Australian radiopharmaceuticals specialist Telix Pharmaceuticals have announced a collaboration, sending the latter company’s shares up by 8% in Monday’s trading. 13 April 2026
Biotechnology
US clinical-stage biotech C4 Therapeutics (C4T) announced that it has entered into a new collaboration agreement with Roche to advance research in the emerging degrader-antibody conjugate (DAC) modality. 10 April 2026
Most Read
Features
Company Spotlight
A Vienna-based pharmaceutical company specializing in the commercialization and distribution of innovative medicines across Central and Eastern Europe, the Middle East, and North Africa.
Recent news
Biotechnology
Belgium’s largest pharma company UCB announced that it has entered into a definitive agreement to acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to UCB’s epilepsy portfolio. 18 April 2026
Biotechnology
For most of oncology’s history, the fight against cancer has begun once the disease is diagnosed. UK-based Athernal Bio is building its platform around an earlier and potentially more powerful point of intervention: addressing biological changes in the body that accumulate silently before cancer develops. 17 April 2026
Pharmaceutical
Spanish plasma-derived medicines company Grifols announced that it has successfully completed the refinancing of its 2027 debt maturities through a new credit agreement structured as a Term Loan B (TLB), alongside a revolving credit facility. 17 April 2026
Pharmaceutical
Recently-launched US obesity company Kailera Therapeutics has announced the pricing of its initial public offering of 39,062,500 shares of its common stock at a price to the public of $16.00 per share. All of the shares of common stock are being offered by Kailera. 17 April 2026
Pharmaceutical
Achieve Life Sciences, a late-stage specialty pharma company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, has appointed Andrew Goldberg as its new chief executive and member of the board. 17 April 2026
Refine search
In Brief
Pharmaceutical
10 April 2026 Shares of Indian drug major Sun Pharmaceutical Industries declined sharply in trade on the Bombay Stock Exchange, as investor sentiment turned cautious following reports of a potential large acquisition.
Pharmaceutical
7 April 2026 Pharma companies are just “scratching the surface” of the huge potential market for weight-loss drugs and should focus more on widening access, according to the head of the company behind semaglutide, trade named Wegovy and Ozempic.
Conferences
23 February 2026 26 February 2026 London, UK, ExCeL London
18 April 2026 24 April 2026 Louisiana, USA, Ernest N. Morial Convention Center
20 April 2026 22 April 2026 Copenhagen, Denmark, Bella Center Copenhagen
21 April 2026 23 April 2026 New York, USA, Jacob K. Javits Convention Center
21 April 2026 23 April 2026 Tokyo, Japan, Tokyo Big Sight
22 April 2026 24 April 2026 Barcelona, Spain, CCIB
Insights
Generics
The Russian Ministry of Health has begun more active cancelling of tenders for drug procurements, waiting for the launch of cheaper generics, as the federal budget experiences a shortage of funds for procurements of expensive original drugs. 13 April 2026
Pharmaceutical
Central and Eastern Europe has long been used by pharma companies as a lower-cost extension of Western operations. That role is changing. Poland, Hungary, and the Czech Republic are now used more directly for manufacturing and clinical development within the EU framework, rather than as peripheral sites. 10 April 2026
Biotechnology
Late last year, Julie Dehaene-Puype stepped into the role of Regional President at Kyowa Kirin International (KKI), a specialty pharma developing innovative treatments for rare and genetic diseases, including bone and mineral disorders, rare blood cancers and other inherited genetic conditions. 8 April 2026
Biotechnology
Rare disease drug pricing has long rested on a simple trade-off. Small patient populations and high development costs justified higher prices, and payers largely accepted that logic because the overall budget impact remained limited. That balance is becoming harder to maintain as orphan drugs now account for a growing share of new launches and an increasing portion of drug spending. 8 April 2026
Pharmaceutical
Europe remains a major base for clinical research, with established academic centers, large hospital networks, and access to diverse patient populations. Multinational trials continue to rely on European sites, but sponsors are allocating a growing share of studies to the USA and parts of Asia, where timelines can be shorter and more predictable. 7 April 2026
Generics
India has moved ahead in developing indigenous capacity for cell and gene therapies, with regulatory bodies issuing national guidelines to ensure safe and ethical deployment of CRISPR-based technologies. 3 April 2026
Pharmaceutical
With unprecedented patent cliffs looming, putting an estimated $200 to $400 billion in annual global sales at risk, senior strategy consultant and Nmblr founder, Janice MacLennan, is issuing a stark warning to biopharma organizations tasked with delivering innovative new therapies to market. 1 April 2026
One to Watch Companies
One to watch
A privately-held French biotech advancing a clinical pipeline of gamma delta T-cell-focused antibodies for cancer and autoimmune diseases.
One to watch
MaaT Pharma, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases.
One to watch
Privately-held GAIA is focused on the development of evidence-based, safe and accessible AI-powered digital therapeutics (DTx) that help patients restore and maintain their mental and physical health.
One to watch
Exsilio Therapeutics is developing genomic medicines that can be delivered in lipid nanoparticles to durably and safely treat a broad range of diseases, including genetic diseases, cancer, and autoimmune conditions.
Boardroom
Pharmaceutical
UK-based specialty pharma company CNX Therapeutics today announced the appointment of David Flint as chief corporate development officer (CCDO), effective April 7, 2026. 16 April 2026
Biotechnology
Enodia Therapeutics, a privately-held French biotech developing small molecule therapies targeting a unique form of protein degradation at the point of synthesis, has appointed Yvonne McGrath as chief scientific officer (CSO). 15 April 2026
Biotechnology
French immunotherapy company OSE Immunotherapeutics
provided a senior management update. 15 April 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze